Skip to main content
. 2021 Nov 4;22(21):11951. doi: 10.3390/ijms222111951

Table 1.

Final concentrations and respective targets of BRAFi/MEKi utilized in the experiments.

Inhibitor/
Inhibitor Combinations
Final Concentration Target
vemurafenib (vemu, V) 60 µM BRAFV600E
dabrafenib (dabra, D) 1 µM BRAFV600E
trametinib (tram, T) 30 nM MEK 1/2
cobimetinib (cobi, C) 0.5 µM MEK 1/2